NCT07255859 is a NA clinical trial of Amsler Grid in Maculopathy, sponsored by Tan Tock Seng Hospital.

Who is sponsoring NCT07255859?

NCT07255859 is sponsored by Tan Tock Seng Hospital.

What drugs are being tested in NCT07255859?

Interventions in NCT07255859: Amsler Grid, CRYSTALSIGHT.

What condition does NCT07255859 study?

NCT07255859 studies Maculopathy.

Is NCT07255859 still recruiting?

NCT07255859 is currently recruiting now. Last updated 8 January 2026.

Last reviewed 2026-01-08 · How we verify

NCT07255859

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CRYSTALSIGHT Cohort 2.0

Recruiting now NA Last updated 8 January 2026

What this trial tests

NA trial testing Amsler Grid in Maculopathy in 60 participants. Currently enrolling.

Timeline

16 June 2025

Primary endpoint
31 July 2026

31 July 2027

Quick facts

Lead sponsor	Tan Tock Seng Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	60
Start date	16 June 2025
Primary completion	31 July 2026
Estimated completion	31 July 2027
Sites	1 location across Singapore

Drugs / interventions tested

Amsler Grid
CRYSTALSIGHT

Conditions studied

Maculopathy — all drugs for Maculopathy →

Sponsor

Tan Tock Seng Hospital

Who can join

Adults 55 to 99, any sex, with Maculopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate OCCUTRACK's CRYSTALSIGHT device through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Tan Tock Seng Hospital trials

Trials by the same sponsor.

NCT07078240 — Examining Nurses' Trust and Acceptance of FAIR, an AI-powered Falls Risk Recommender · NA · not yet recruiting
NCT07257341 — Pilot Study of Normative Range of Field of Binocular Single Vision in Adults in Singapore · recruiting
NCT07151729 — Use of Anodal tDCS to Enhance Upper Limb Recovery in Stroke · NA · recruiting
NCT07122752 — Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy · active not recruiting
NCT07255885 — CRYSTALSIGHT: ''Cohort 1.5" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07255859 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tan Tock Seng Hospital
Last refreshed: 8 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07255859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing